ImmuPharma (LON:IMM) Trading Up 20.6% - Time to Buy?

Key Points

• ImmuPharma's shares experienced a significant increase of 20.6%, trading up to GBX 13.08 ($0.18) on Friday, with trading volume rising by 247% compared to average daily volume.
• The company reported a negative earnings per share (EPS) of GBX (0.38) in its last quarterly earnings, and analysts predict an EPS of -339.0000022 for the current year.
• ImmuPharma PLC focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program, P140 (Lupuzor™), showing potential for Lupus treatment and other related conditions.

ImmuPharma plc (LON:IMM - Get Free Report) shares were up 20.6% during trading on Friday . The company traded as high as GBX 13.19 ($0.18) and last traded at GBX 13.08 ($0.18). Approximately 27,867,863 shares changed hands during mid-day trading, an increase of 247% from the average daily volume of 8,024,198 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Performance

The stock has a market capitalization of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53. The stock has a 50-day simple moving average of GBX 2.88 and a 200 day simple moving average of GBX 2.86.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.